ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. Event: Canaccord Genuity 45th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 12:30pm ET/9:30am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com ...

For the quarter ended June 2025, Penumbra (PEN) reported revenue of $339.46 million, up 13.4% over the same period last year. EPS came in at $0.86, compared to $0.64 in the year-ago quarter.The reported revenue represents a surprise of +3.54% over the Zacks Consensus Estimate of $327.85 million. With the consensus EPS estimate being $0.81, the EPS surprise was +6.17%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

公司业绩表现 - 季度每股收益0 86美元 超出Zacks一致预期0 81美元 同比增长34 4% [1] - 季度营收3 3946亿美元 超出预期3 54% 同比增长13 4% [2] - 过去四个季度均超预期 最近两季度盈利超预期幅度分别为6 17%和25 76% [1][2] 市场表现与展望 - 年初至今股价下跌3 1% 同期标普500指数上涨8 6% [3] - 当前Zacks评级为3级(持有) 预计短期表现与市场持平 [6] - 下季度预期每股收益0 96美元 营收3 4193亿美元 全年预期每股收益3 72美元 营收13 5亿美元 [7] 行业比较 - 所属医疗仪器行业在Zacks 250多个行业中排名后37% [8] - 同业公司Artivion预计下季度每股收益0 11美元 同比增长57 1% 营收1 0825亿美元 同比增长10 4% [9][10]

Penumbra (PEN) Q2 2025 Earnings Call July 29, 2025 04:30 PM ET Company ParticipantsCecilia Furlong - Director - Business DevelopmentAdam Elsesser - Co-Founder, President, Chairman, CEO & DirectorMaggie Yuen - CFOJason Mills - EVP - StrategyTravis Steed - MD - Equity ResearchRichard Newitter - Managing DirectorBill Plovanic - MD & Equity Research - Medical TechnologyJoanne Wuensch. - Managing DirectorChris Pasquale - Partner - Medical Devices & SuppliesConference Call ParticipantsLawrence Biegelsen - Senior ...

Penumbra (PEN) Q2 2025 Earnings Call July 29, 2025 04:30 PM ET Speaker0Ladies and gentlemen, good afternoon. My name is Abby, and I'll be your conference operator today. At this time, I would like to welcome everyone to Penumbra's Second Quarter twenty twenty five Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.If you would like to ask a question during that time, simply press star followed by the n ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 (State or other jurisdiction of incorporation or organization) Delaware 05-0605598 (I.R.S. Employer Identification No.) One Penumbra Place OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to _____ Commis ...

Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2025 Financial Results ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue increased to $339.5 million for the second quarter of 2025 compared to $299.4 million for the second quarter of 2024, an increase of 13.4%, or 12.7% in constant currency . The United States re ...

ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024. U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% c ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Penumbra (PEN) , which belongs to the Zacks Medical - Instruments industry.This medical device maker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 16.18%.For the last reported quarter, Penumbra came out with earnings of $0.83 per share versus the Za ...

核心观点 - 华尔街预计Penumbra在2025年第二季度财报中将实现营收和盈利同比增长，实际业绩与预期对比将显著影响短期股价[1][2] - 公司预计每股收益0.81美元（同比增长26.6%），营收3.2785亿美元（同比增长9.5%）[3] - 盈利预期修正趋势显示分析师近期对Penumbra持乐观态度，盈利ESP达+1.28%，结合Zacks Rank 3评级预示大概率超预期[12] 财务预期分析 - 过去30天季度EPS共识预期保持稳定，反映分析师对初始预测的集体重新评估[4] - 最准确预期高于共识预期，显示分析师近期对公司盈利前景转为看涨[12] - 上季度实际EPS 0.83美元远超预期的0.66美元，实现25.76%的正向意外[13] 历史表现 - 过去四个季度公司全部超出EPS共识预期[14] - 最近季度25.76%的超预期幅度显示公司持续超越分析师预测的能力[13] 预测模型 - Zacks盈利ESP模型通过对比最新修正预期与共识预期来预测业绩偏离方向[8] - 正向ESP读数配合Zacks Rank 1-3时，预测准确率近70%[10] - 当前+1.28%的ESP读数与Zacks Rank 3组合形成强力的超预期信号[12] 市场影响 - 财报发布日期为7月29日，关键数据超预期可能推动股价上涨[2] - 历史数据显示盈利超预期并非股价上涨的唯一决定因素，需结合其他市场催化剂综合判断[15] - 提前识别可能超预期的股票（如Penumbra）可提高投资成功概率[16]